健友股份：关于子公司获得美国FDA醋酸奥曲肽注射液药品增加生产场地注册批件的公告

Core Viewpoint - Jianyou Co., Ltd. announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. FDA for the production of Acetate Octreotide Injection in multiple concentrations [2] Group 1: Company Developments - Meitheal Pharmaceuticals, Inc. has been granted an approval letter by the U.S. FDA for the production of Acetate Octreotide Injection at concentrations of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [2] - The approval allows production to take place at the facilities of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. [2]